-
-
-
-
-
-
-
BioBlast Pharma (ORPN) Reports Q3 Loss of $0.28/Share
-
-
-
-
-
-
-
Lower Than Expected R&D Expenses Drive 3Q EPS Beat for BioBlast Pharma (ORPN); Oppenheimer Reiterates Outperform
-
-
-
-
-
-
-
Bio Blast Pharma (ORPN) Posts Q2 Loss of 10c/Share
1,220,460 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

